

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Cancelled)
2. (Cancelled).
3. (Cancelled)
4. (Cancelled)
5. (Cancelled)
6. (Currently Amended) A medical device comprising:  
an implantable structure;  
trichostatin A, in therapeutic dosages, releasably affixed  
to the implantable structure for the treatment of restenosis following  
vascular injury, the trichostatin A being incorporated into a basecoat  
polymeric material, the concentration of trichostatin A being less than  
100 nano molar;  
rapamycin, in therapeutic dosages, releasably affixed to  
the implantable structure for the treatment of restenosis following  
vascular injury, the rapamycin being incorporated into the basecoat  
polymeric material the rapamycin and the trichostatin A potentiating  
each others effectiveness; and  
a topcoat polymeric material affixed to the basecoat polymeric  
material to control the elution rate of the and the rapamycin, the

topcoat polymeric material and the basecoat polymeric material being immiscible polymeric materials, wherein the basecoat polymeric material includes a copolymer polyvinylidenefluoride-co-hexafluoropropylene with a sixty/forty weight ratio of VDF:HFP and the topcoat comprises a four hundred ninety microgram BMA poly(n-butylmethacrylate) layer, wherein the basecoat and the topcoat are mixed and precipitated from solution to create a phase separation of two distinct layers.

7. (Original) The medical device according to Claim 6, wherein the implantable structure comprises a stent.

8. (Original) The medical device according to Claim 6, wherein the implantable structure comprises a stent-graft.

9. (Cancelled)

10. (Cancelled)

11. (Cancelled)

12. (Cancelled)

13. (Cancelled)

14. (Cancelled)